Status: Recruiting
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.
Participants needed: 136
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Shanghai CureGene Pharmaceutical Co., Ltd.Updated: Jun 29, 2026Locations: 1
Eligibility criteria
Participants must be fully informed about the study, willing to participate, and... [+10]
Difficulty with venous blood collection or a history of fainting upon seeing blo... [+25]